Clinical trial
A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With…
NCT00316238 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00316238 |
|---|---|
| Title | A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia |
| Official title | A Double-Blind Dose-Response Study Comparing Rapid Acting Intramuscular Olanzapine and Intramuscular Placebo in Agitated Patients With Schizophrenia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | olanzapine-RAIM, placebo |
| Enrollment | 160 |
| Start date | Apr 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Apr 20, 2006 |
| Last update posted | Jun 8, 2007 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: